No improvement in clinical outcomes occurred among inpatients with COVID-19 who received nirtmatrelvir-ritonavir or molnupiravir in addition to usual care.

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...

Many patients experience long-lasting health problems after COVID-19. The study aimed to assess 3-year trajectories of a comprehensive set of patient-reported outcome measures (PROMs) in patients ...

A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

The findings could have sweeping implications for drug developers already working to design antivirals based on flawed assumptions, and underscore the importance of rigorous validation.

The COVID pandemic illustrated how urgently we need antiviral medications capable of treating coronavirus infections. To aid this effort, researchers quickly homed in on part of SARS-CoV-2's ...